The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Neurocrine Biosciences, Inc shares valued at $2,649,738 were sold by Onyia Jude on Jul 02 ’25. At $130.13 per share, Onyia Jude sold 20,362 shares. The insider’s holdings dropped to 18,289 shares worth approximately $2.44 million following the completion of this transaction.
Also, JUDE ONYIA purchased 80,181 shares, netting a total of over 10,263,168 in proceeds.
Before that, GORMAN KEVIN CHARLES had sold 9,613 shares from its account. In a trade valued at $1,157,211, the Director traded Neurocrine Biosciences, Inc shares for $120.38 each. Upon closing the transaction, the insider’s holdings decreased to 9,613 shares, worth approximately $68.7 million.
As published in a research note from Needham on April 15, 2025, Neurocrine Biosciences, Inc [NBIX] has been rated up from a Hold to a Buy and the price target has been revised to $138. Analysts at RBC Capital Mkts upgraded the stock from ‘”a Sector perform”‘ to ‘”an Outperform”‘ outlook in a report released in mid April. As of February 11, 2025, Deutsche Bank has initiated its “Hold” rating for NBIX.
Analyzing NBIX Stock Performance
On last trading session,, Neurocrine Biosciences, Inc [NASDAQ: NBIX] rose 3.71% to $133.51. The stock’s lowest price that day was $128.935, but it reached a high of $133.69 in the same session. During the last five days, there has been a surge of approximately 4.30%. Over the course of the year, Neurocrine Biosciences, Inc shares have dropped approximately -4.00%. Shares of the company reached a 52-week high of $154.61 on 01/30/25 and a 52-week low of $84.23 on 04/09/25.
Support And Resistance Levels for Neurocrine Biosciences, Inc (NBIX)
According to the 24-hour chart, there is a support level at 130.40, which, if violated, would cause prices to drop to 127.29. In the upper region, resistance lies at 135.15. The next price resistance is at 136.80. RSI (Relative Strength Index) is 71.14 on the 14-day chart, showing overbought technical sentiment.
Is Neurocrine Biosciences, Inc subject to short interest?
Stocks of Neurocrine Biosciences, Inc saw a sharp steep in short interest on 2025-06-13 dropping by -0.53 million shares to 3.5 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 4.03 million shares. A decline of -15.29% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 3.39 of the overall float, the days-to-cover ratio (short ratio) decline to 3.39.
Which companies own the most shares of Neurocrine Biosciences, Inc (NBIX)?
In terms of Neurocrine Biosciences, Inc share price expectations, FactSet research, analysts set an average price target of 158 in the next 12 months, up nearly 22.73% from the previous closing price of $128.74. Analysts anticipate Neurocrine Biosciences, Inc stock to reach 168 by 2025, with the lowest price target being 150. In spite of this, 14 analysts ranked Neurocrine Biosciences, Inc stock as Buy at the end of 2025. On August 29, 2024, Piper Sandler assigned a price target of “an Overweight” to the stock and upgraded coverage with a $159.
